There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Rajasimhan Rajagovindan |
| Institution: | Vigil Neuro |
| Department: | R&D |
| Country: | |
| Proposed Analysis: | Analysis goals: - Understand the influence of TREM2 genetic variants on baseline and longitudinal biomarker profiles (e.g. amyloid and tau levels in brain, CSF, blood) - Understand the influence of TREM2 genetic variants on longitudinal change in clinical scales (CDR, MMSE, ADAS-Cog) - Estimate the prevalence/incidence of TREM2 variants in biomarker confirmed SCI/MCI/AD patients - Leverage longitudinal change data to inform on sample size for early proof-of-concept therapeutic studies - Leverage baseline and longitudinal data (demog, biomarkers, clinical) to inform on patient selection criteria to identify a patient population that is relatively homogeneous and demonstrate measurable decline over 6-12 months for early proof-of-concept therapeutic studies - Investigate correlation between biomarker changes and disease progression to help prioritize biomarker panel for therapeutic trials |
| Additional Investigators |
